Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1674 1682
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17878884 | METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA | Final Rejection | Genzyme Corporation |
| 18485592 | Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17795943 | DELIVERY OF COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18020145 | DEVELOPMENT AND APPLICATION OF POLYMER-COATED GOLD NANOPARTICLE-APTAMER NANOCONSTRUCT HAVING SENSITIVITY TO REACTIVE OXYGEN SPECIES | Non-Final OA | POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION |
| 17780600 | RNA INTERFERENCE-INDUCING NUCLEIC ACID COMPRISING 8-OXOGUANINE, MODIFIED NUCLEIC ACID BINDING TO MICRORNA COMPRISING 8-OXOGUANINE, AND USES THEREOF | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 16763827 | COMPOSITIONS AND METHODS FOR EFFICIENT GENOME EDITING | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17768023 | NOVEL RNA APTAMER INTERVENES ESTROGEN RECEPTOR INTERACTION WITH COACTIVATOR MED1 TO OVERCOME BREAST CANCER METASTASIS | Final Rejection | University of Cincinnati |
| 17970138 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 17913100 | MICRORNAS FOR THE PREVENTION OF CLINICAL VENOUS THROMBOEMBOLIC DISEASE | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 17612000 | DNA NANOARCHITECTURES FOR PATTERN-RECOGNIZED TARGETING OF DISEASES | Final Rejection | RENSSELAER POLYTECHNIC INSTITUTE |
| 17788462 | COMPOSITION COMPRISING MIR-335 | Non-Final OA | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 18071353 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | Final Rejection | ARBUTUS BIOPHARMA CORPORATION |
| 17967888 | FMRP AND CANCER TREATMENT | Final Rejection | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) |
| 18661524 | NCOVSHRNA*2RBD DRUG FOR TARGETED DELIVERY SHRNA by RBD, SYNTHESIS METHOD, AND APPLICATION THEREOF | Non-Final OA | Binghuan WENG |
| 18042015 | COMPOSITIONS AND METHOD FOR TREATING THALASSEMIA | Non-Final OA | St. Jude Children's Research Hospital, Inc. |
| 17425272 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND RELATED DISORDERS | Non-Final OA | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18044565 | IMMUNOADJUVANT-BASED HYDROGEL COMPOSITION AND USE THEREOF | Final Rejection | SOOCHOW UNIVERSITY |
| 18001284 | METHOD FOR TREATING AND PROGNOSING CANCER LIKE GLIOBLASTOMA | Non-Final OA | UNIVERSITÉ DE NANTES |
| 18043520 | DUX4 INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | SAINT LOUIS UNIVERSITY |
| 17796563 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Final Rejection | MAZE THERAPEUTICS, INC. |
| 18299121 | SYSTEMS, METHODS AND COMPOSITION OF USING RNASE III MUTANTS TO PRODUCE SRNA TO CONTROL HOST PATHOGEN INFECTION | Non-Final OA | Pebble Labs Inc. |
| 18028992 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | Non-Final OA | EMPIRICO INC. |
| 18027895 | CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS | Non-Final OA | TriSalus Life Sciences, Inc. |
| 17935688 | Thiomorpholino Oligonucleotides For The Treatment of Muscular Dystrophy | Final Rejection | Murdoch University |
| 18014322 | DIAGNOSIS AND TREATMENT OF CHRONIC DIABETIC COMPLICATIONS USING LONG NONCODING RNAS AS TARGETS | Non-Final OA | THE UNIVERSITY OF WESTERN ONTARIO |
| 17985978 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1) | Non-Final OA | Korro Bio, Inc. |
| 17998085 | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | Non-Final OA | Takeda Pharmaceuticals U.S.A., Inc. |
| 17995613 | Bispecific Aptamer Compositions for the Treatment of Retinal Disorders | Non-Final OA | Drive Therapeutics, L.L.C. |
| 17802916 | FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING | Non-Final OA | MICROCURES, INC. |
| 17846288 | Compositions and Methods for Simultaneously Modulating Expression of Genes | Non-Final OA | Versameb AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy